argenx SE (ARGNF)
USD 697.42
(0.33%)
USD 697.42
(0.33%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -2.02 Billion USD | -157.36% |
| 2022 | -788.31 Million USD | 40.42% |
| 2021 | -1.32 Billion USD | -9.36% |
| 2020 | -1.2 Billion EUR | -232.59% |
| 2019 | -363.79 Million EUR | -13.16% |
| 2018 | -321.48 Million EUR | -40.4% |
| 2017 | -228.98 Million EUR | -142.2% |
| 2016 | -94.54 Million EUR | -143.5% |
| 2015 | -38.82 Million EUR | 0.78% |
| 2014 | -39.13 Million EUR | -24.73% |
| 2013 | -31.37 Million EUR | -72.68% |
| 2012 | -18.16 Million EUR | 35.85% |
| 2011 | -28.32 Million EUR | -169.71% |
| 2010 | -10.5 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -1.4 Billion USD | -147.66% |
| 2024 Q1 | 2.94 Billion USD | 245.24% |
| 2023 FY | -2.02 Billion USD | -157.36% |
| 2023 Q1 | 2.02 Billion USD | 356.41% |
| 2023 Q2 | -1.09 Billion USD | -154.39% |
| 2023 Q3 | 1.88 Billion USD | 271.83% |
| 2023 Q4 | -2.02 Billion USD | -207.41% |
| 2022 Q4 | -788.31 Million USD | -129.74% |
| 2022 Q2 | -1.35 Billion USD | 0.0% |
| 2022 FY | -788.31 Million USD | 40.42% |
| 2022 Q3 | 2.65 Billion USD | 295.25% |
| 2021 Q2 | -1.57 Billion USD | 0.0% |
| 2021 FY | -1.32 Billion USD | -9.36% |
| 2021 Q4 | -1.32 Billion USD | 0.0% |
| 2020 Q2 | -1.34 Billion EUR | 0.0% |
| 2020 FY | -1.2 Billion EUR | -232.59% |
| 2020 Q4 | -1.2 Billion EUR | 0.0% |
| 2019 FY | -363.79 Million EUR | -13.16% |
| 2019 Q4 | -324.76 Million EUR | 0.0% |
| 2019 Q2 | -186.58 Million EUR | 0.0% |
| 2018 FY | -321.48 Million EUR | -40.4% |
| 2018 Q4 | -321.48 Million EUR | 0.0% |
| 2018 Q2 | -162.87 Million EUR | 0.0% |
| 2017 Q2 | -86.4 Million EUR | 0.0% |
| 2017 FY | -228.98 Million EUR | -142.2% |
| 2017 Q4 | -228.98 Million EUR | 0.0% |
| 2016 Q4 | -94.54 Million EUR | 0.0% |
| 2016 Q2 | -113.36 Million EUR | 0.0% |
| 2016 FY | -94.54 Million EUR | -143.5% |
| 2015 Q4 | -38.82 Million EUR | 0.0% |
| 2015 FY | -38.82 Million EUR | 0.78% |
| 2015 Q2 | -29.39 Million EUR | 0.0% |
| 2014 Q1 | -28.07 Million EUR | 10.51% |
| 2014 Q4 | -39.13 Million EUR | 0.0% |
| 2014 Q2 | -28.15 Million EUR | -0.29% |
| 2014 FY | -39.13 Million EUR | -24.73% |
| 2013 Q4 | -31.37 Million EUR | 0.0% |
| 2013 FY | -31.37 Million EUR | -72.68% |
| 2012 FY | -18.16 Million EUR | 35.85% |
| 2011 FY | -28.32 Million EUR | -169.71% |
| 2010 FY | -10.5 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | -154873487.786% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 36019.106% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 4841.065% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -812673.015% |
| Rebus Holdings, Inc. | 305 Thousand USD | 665294.754% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -32080.764% |
| Qrons Inc. | 351.42 Thousand USD | 577415.915% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 326089.935% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 4771.096% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -9941315.131% |
| Skye Bioscience, Inc. | -5.72 Million USD | -35360.69% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 12970.926% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 49367.416% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 504977.205% |
| SQZ Biotechnologies Company | -36.23 Million USD | -5498.664% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 90583.192% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 218917.368% |
| Mesoblast Limited | 55.85 Million USD | 3732.129% |
| Marizyme, Inc. | 18.56 Million USD | 11025.956% |
| Genus plc | 190.6 Million USD | 1164.451% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 90842.238% |
| Pharming Group N.V. | 109.8 Million USD | 1947.696% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 235946.001% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 167236.013% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 298459.412% |
| ContraFect Corporation | -6.02 Million USD | -33568.171% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 1506976.908% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 175692.269% |
| IMV Inc. | 7.67 Million USD | 26549.885% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 36975.361% |
| MultiCell Technologies, Inc. | 90.04 USD | 2253269757.93% |
| ONE Bio Corp. | 9.04 Million USD | 22542.878% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -276317.549% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 15771.59% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 148410.454% |
| Q BioMed Inc. | 4.06 Million USD | 50071.429% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 6740.191% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 201430.931% |
| Biomind Labs Inc. | 711.4 Thousand USD | 285289.527% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 3450.927% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 101573.048% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 15942.187% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 564122.129% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 1451305.974% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 10212230.669% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 92237.216% |
| GB Sciences, Inc. | 1.74 Million USD | 116212.026% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -1103804.499% |
| HST Global, Inc. | 96.79 Thousand USD | 2096164.798% |
| CSL Limited | 10.52 Billion USD | 119.275% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 983939.354% |
| Halberd Corporation | 144.72 Thousand USD | 1402000.208% |
| Enzolytics Inc. | 981.65 Thousand USD | 206775.658% |
| Agentix Corp. | 37.63 Thousand USD | 5391516.651% |
| Resverlogix Corp. | 6.45 Million USD | 31550.07% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -301322.843% |
| MetaStat, Inc. | - USD | Infinity% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | -4215.588% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 28792.576% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 75003.373% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -22850.952% |
| AVAX Technologies, Inc. | -5.9 Million USD | -34268.505% |
| Zenith Capital Corp. | 10.06 Thousand USD | 20159519.714% |
| Genscript Biotech Corporation | -1.06 Billion USD | -91.16% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 1012335.571% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 85129.97% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 1233372.344% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -11075585.118% |
| Kadimastem Ltd | -253.1 Thousand USD | -801491.453% |
| Helix BioMedix, Inc. | -2.57 Million USD | -78842.363% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 10106.135% |
| BioStem Technologies, Inc. | 4.47 Million USD | 45467.599% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 1008201.205% |
| LadRx Corporation | -2.03 Million USD | -99525.577% |
| Cell Source, Inc. | 9.23 Million USD | 22076.282% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 319518.987% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 319518.987% |
| NovAccess Global Inc. | 2.17 Million USD | 93231.815% |
| Affymax, Inc. | -5.59 Million USD | -36148.776% |
| Itoco Inc. | 228.3 Thousand USD | 888755.089% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 1492017.729% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 41028.868% |
| Mobile Lads Corp. | 484.23 Thousand USD | 419081.81% |
| CytoDyn Inc. | 20.26 Million USD | 10113.049% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -313577025.193% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -21889947.193% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 26428.101% |
| SYBLEU INC | 473.71 Thousand USD | 428384.577% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 45620.17% |
| International Stem Cell Corporation | 2.59 Million USD | 78433.745% |
| Bioxytran, Inc. | 1.89 Million USD | 106942.332% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 3250775.34% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 93127.833% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 59181.072% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 23820.846% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 262697.155% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -162207.52% |
| Neutra Corp. | 52.18 Thousand USD | 3887742.516% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -81412.415% |
| PureTech Health plc | -167.19 Million USD | -1113.445% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -828310.668% |
| IXICO plc | -4.44 Million USD | -45547.526% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 15447.939% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 3798.828% |
| CSL Limited | 10.52 Billion USD | 119.275% |
| Cellectis S.A. | -43.81 Million USD | -4530.069% |